ATLAS stands up 10-year tamoxifen regime By Lynda Williams.

The ATLAS study results were simultaneously released in The Lancet. Related StoriesSausages With Antioxidants From Berries To Prevent CancerStudy shows rare HER2 missense mutations usually do not spread breasts cancer on the ownMD Anderson study reveals why chemotherapy medications not effective for many pancreatic malignancy patientsThe ATLAS trial included 6846 ladies with ER-positive breast malignancy, half of whom experienced node-positive disease. Over typically 7.1 women-years of follow-up, 1328 breast cancer recurrences had been reported, including 900 situations in years 5-9 and 379 cases in years 10-14 after diagnosis. The likelihood of recurrent disease was significantly reduced women assigned to receive tamoxifen for 10 years versus those provided treatment for 5 years, with a rate ratio of 0.90 for years 5-9 and 0.75 after a decade.‘Further investigation and in-depth analysis can inform optimal strategies to mitigate and prevent injuries among this specific group of players.’ The researchers caused two Baltimore Orioles trainers to investigate all catcher injuries during Major League Baseball games between 2001 and 2010. A complete of 134 injures were documented. Of these, 114 didn’t involve a collision with a base runner, the researchers statement in a recent problem of the American Journal of Sports Medicine. This means that less than 15 % of catcher injuries were the consequence of connection with another player. Moreover, these run-ins needed less recovery period than other types of injury usually, the researchers said.